Hydroxyurea Use in Sickle Cell Disease: the Battle with Low Prescription Rates, Poor Patient Compliance and Fears of Toxicities

Overview

Journal Expert Rev Hematol

Specialty Hematology

Date 2010 Nov 19

PMID 21082977

Citations 58

Authors

Amanda M Brandow

Julie A Panepinto

Affiliations

Soon will be listed here.

Citing Articles

Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications.

Alsaffar N, Alsaleh M, Alsaleh A, Ghanem N, Al Khamees M, Alqurain M J Clin Med. 2024; 13(20).

PMID: 39458204 PMC: 11508296. DOI: 10.3390/jcm13206254.

Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania.

Kilonzi M, Mlyuka H, Felician F, Mwakawanga D, Chirande L, Myemba D Hemato. 2024; 2(4):713-726.

PMID: 39211482 PMC: 11361318. DOI: 10.3390/hemato2040048.

Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.

Sasi P, Makubi A, Sangeda R, Ngaeje M, Mmbando B, Soka J Commun Med (Lond). 2024; 4(1):160.

PMID: 39122788 PMC: 11315961. DOI: 10.1038/s43856-024-00552-5.

Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and trait blood samples at point of care.

DCosta C, Sharma O, Manna R, Singh M, Singh S, Singh S Bioeng Transl Med. 2024; 9(4):e10643.

PMID: 39036093 PMC: 11256192. DOI: 10.1002/btm2.10643.

Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.

Namaganda P, Nantume P, Mubiru K, Twimukye A, Wiltshire C BMC Health Serv Res. 2024; 24(1):666.

PMID: 38802815 PMC: 11131175. DOI: 10.1186/s12913-024-11125-6.

References

Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C . Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996; 88(6):1960-4. View

Ritter J, Harding I, Warren J . Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends Pharmacol Sci. 2009; 30(10):503-8. DOI: 10.1016/j.tips.2009.07.007. View

Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P . Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001; 97(11):3628-32. DOI: 10.1182/blood.v97.11.3628. View

Zumberg M, Reddy S, Boyette R, Schwartz R, Konrad T, Lottenberg R . Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005; 79(2):107-13. DOI: 10.1002/ajh.20353. View

Berthaut I, Guignedoux G, Kirsch-Noir F, De Larouziere V, Ravel C, Bachir D . Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008; 93(7):988-93. DOI: 10.3324/haematol.11515. View

Baquet C, Mishra S, Commiskey P, Ellison G, DeShields M . Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2008; 100(5):480-8. PMC: 3603001. DOI: 10.1016/s0027-9684(15)31294-3. View

Kinney T, HELMS R, Obranski E, Ohene-Frempong K, Wang W, Daeschner C . Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999; 94(5):1550-4. View

Frei-Jones M, Field J, DeBaun M . Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer. 2008; 52(4):481-5. PMC: 2730199. DOI: 10.1002/pbc.21854. View

Platt O, Thorington B, Brambilla D, Milner P, Rosse W, Vichinsky E . Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991; 325(1):11-6. DOI: 10.1056/NEJM199107043250103. View

10.

Hankins J, Ware R, Rogers Z, Wynn L, Lane P, Scott J . Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106(7):2269-75. PMC: 1895275. DOI: 10.1182/Blood-2004-12-4973. View

11.

Lanzkron S, Haywood Jr C, Segal J, Dover G . Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006; 81(12):927-32. DOI: 10.1002/ajh.20703. View

12.

Heeney M, Ware R . Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008; 55(2):483-501, x. DOI: 10.1016/j.pcl.2008.02.003. View

13.

Brandow A, Brousseau D, Panepinto J . Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol. 2008; 144(5):782-8. PMC: 3118502. DOI: 10.1111/j.1365-2141.2008.07512.x. View

14.

Lanzkron S, Haywood Jr C, Fagan P, Rand C . Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved. 2010; 21(1):277-86. DOI: 10.1353/hpu.0.0272. View

15.

Brousseau D, Panepinto J, Nimmer M, Hoffmann R . The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2009; 85(1):77-8. DOI: 10.1002/ajh.21570. View

16.

Lanzkron S, Haywood Jr C, Hassell K, Rand C . Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008; 100(8):968-73. View

17.

Raphael J, Dietrich C, Whitmire D, Mahoney D, Mueller B, Giardino A . Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer. 2008; 52(2):263-7. DOI: 10.1002/pbc.21781. View

18.

Hankins J, Hinds P, Day S, Carroll Y, Li C, Garvie P . Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer. 2006; 48(7):705-10. DOI: 10.1002/pbc.20903. View

19.

Steinberg M, Barton F, Castro O, Pegelow C, Ballas S, Kutlar A . Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-51. DOI: 10.1001/jama.289.13.1645. View

20.

Alegria M, Chatterji P, Wells K, Cao Z, Chen C, Takeuchi D . Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. 2008; 59(11):1264-72. PMC: 2668139. DOI: 10.1176/ps.2008.59.11.1264. View